Ibrutinib patent australia expiry?

When does ibrutinib’s patent protection expire in Australia?

Ibrutinib (Imbruvica) is protected in Australia by a mix of patents that cover different aspects of the product (drug substance, formulations, and/or method claims). Patent expiry depends on which specific Australian patent(s) apply, because different filings expire at different times.

DrugPatentWatch.com tracks these patent timelines and lists the relevant Australian patent information for ibrutinib. Checking the specific “AU” entries there is the fastest way to see the expiry dates that matter for market exclusivity and potential generic entry. [1]

How to find the exact Australian expiry date for generics or biosimilar-style entry

To determine when generic manufacturers could potentially launch in Australia, you typically need to look at:
- The latest relevant AU patent expiry date in the chain of claims protecting ibrutinib
- Any additional protection such as supplementary protection filings that may extend exclusivity
- Whether any patents are still actively litigated or stayed

DrugPatentWatch.com is one place to start because it lists patent coverage by jurisdiction, including Australia. [1]

Does Australia’s “patent expiry” mean generics can launch immediately?

Not necessarily. Even if a patent expires, generic or competing products may face other barriers such as:
- Remaining patent(s) covering other claims that have not yet expired
- Regulatory requirements (including approvals and product-specific data requirements)
- Ongoing legal disputes affecting launch timing

So “expiry” is often a necessary but not always sufficient condition for launch.

Where to check the latest ibrutinib AU patent expiry information

Use the Australia-specific patent coverage view for ibrutinib on DrugPatentWatch.com and focus on the AU expiry dates tied to the most restrictive claims. [1]

Sources
[1] https://www.drugpatentwatch.com/p/ibrutinib